Josh John, Director, Cardiovascular Marketing (Heart Failure), Boehringer Ingelheim Pharmaceuticals, Inc.
JARDIANCE® was already established as a treatment for adults with type 2 diabetes when, in September 2021, it was granted FDA Breakthrough Therapy designation as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF), and in February 2022, it was approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure regardless of ejection fraction. With this new indication, it was up to Josh John and his team to educate cardiologists about JARDIANCE as a new treatment option for people with heart failure.
To ensure this education resonated, Josh and his team employed innovative new approaches. For example, working with Confideo they developed educational content that used augmented reality (AR) to bring a heart to life before a physician’s eyes. Additionally, they also developed AR patient profiles in which patient actors could pop up off the educational content onto the physician’s desk to talk about having heart failure while a KOL voiceover offered perspective on how physicians could help similar patients.
Josh and the team also partnered with Bionical Solutions on programs that allowed representatives to develop patient education materials. For instance, the Put Your Heart 1st™ video program worked with physician practices to develop videos about heart failure for patients.
As a result of these efforts and more, Josh and his amazing team are providing education and bringing JARDIANCE to many more patients with heart failure.